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The Continuing Diabetic
Drug-Eluting Stents Saga
From Very-Late Stent Thrombosis to
Very-Late Late Loss*
Koon-Hou Mak, MD
Singapore
Unlike various atherosclerotic risk factors in which the
population attributable to risk fell marginally from the
period 1952 to 1974 to the period 1975 to 1998, it rose for
diabetes (1). This adverse trend is worrisome as the preva-
lence of diabetes is rapidly growing worldwide, rising from
171 million in 2000 to a projected 366 million in 2030 (2).
he increase may potentially reverse the decline in cardio-
ascular disease, a condition that accounts for 58% of
iabetic deaths (3). Furthermore, management of patients
ith diabetes is costly. In the U.S., the 2002 expenditure for
iabetes care was estimated to be $132 billion (3). From
009 to 2034, the cost is expected to double (4), and a
ubstantial component of that is related to hospitalization
3), including the use of various investigative and therapeutic
rocedures.
See page 317
Several early clinical studies have shown outcomes fol-
lowing coronary revascularization among patients with dia-
betes were consistently poorer than for patients without
diabetes (5). Undoubtedly, coronary stents and potent anti-
latelet agents have improved results with percutaneous
oronary intervention. A collaborative meta-analysis has
hown that although there was no overall difference in
ortality between patients with multivessel disease under-
oing bare-metal stenting (BMS) versus coronary artery
ypass grafting (CABG), surgery afforded better survival for
hose with diabetes (6).
The advent of drug-eluting stents (DES) was likened to
n interventional cardiologist entering the Promised Land,
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cientific and Eli Lilly.estowed with a device without fear of restenosis (7).
owever, the euphoria for treating diabetes patients with
ES was cut short by an early meta-analysis comparing
irolimus-eluting stents (SES) with BMS (8). After 4 years,
he risk of dying was roughly 3 times higher among diabetic
atients receiving SES. A subsequent, more comprehensive
tudy involving 3,852 individuals with and 10,947 without
iabetes found that there was no difference in the frequency
f death, myocardial infarction, or both events among those
eceiving DES or BMS (9). Notably, the stent thrombosis
ate was comparable between both treatment groups. These
ndings were also observed in contemporary large angio-
lasty registries (10–12). In this issue of JACC: Cardiovas-
ular Interventions, the investigators of the ARTS (Arterial
evascularization Therapies Study), parts I and II (13) provided
dditional evidence for the long-term safety of DES com-
ared with BMS among patients with diabetes and multi-
essel disease, with similar death and stent thrombosis rates.
owever, a favorable and important finding was that myocar-
ial infarction occurred 2.5 times less frequently among
iabetics treated with DES versus BMS (10.7% vs. 4.4%;
 0.048). Not only was this benefit (13.8% vs. 16.9%)
bserved in the separate Massachusetts Data Analysis Cen-
er Registry (14), but also the 3-year mortality rate (17.5%
s. 20.7%) was significantly lower for patients with diabetes
reated with DES versus BMS.
Notably in ARTS, there was no difference in mortality
nd myocardial infarction rates between patients with dia-
etes undergoing CABG or receiving SES. Taken together
ith similar findings from recent studies (15,16), DES
mplantation in diabetic patients is likely to be safe com-
ared with cardiac surgery. However, the reason for the
utcome improvement among studies over time is uncer-
ain. Although it was shown that use of dual antiplatelet
gents 6 months was associated with superior outcome
9), most patients in ARTS II receiving SES were treated
ith dual therapy for only 3 months. Despite coronary
esions being more complex in ARTS II, perhaps greater
are in stent deployment and a return to the high-pressure
ost-dilation technique (14.9 vs. 16.2 atm, p 0.01) played
a role in improving outcome.
A principal limitation of DES compared with CABG
among patients with diabetes and multivessel disease is the
need for repeat revascularization procedures. At 5 years, the
ARTS investigators reported this rate to be 31.4% and
10.4% for the SES and CABG groups, respectively. Al-
though diabetic patients treated with SES were 40% less
likely to require another revascularization procedure than
those treated with BMS, the investigators described a
disturbing “catch-up” phenomenon. After the second year,
the rate of increase of repeat revascularization procedures
accelerated, and the superiority provided by SES over BMS
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325diminished. The underlying mechanism for this unfavorable
trend was unclear. Although the risk of acquired late
malapposition was higher among diabetic patients treated
with SES versus BMS (14.7% vs. 0%; p  0.001) at
9 months (17), no patient in that study suffered from stent
thrombosis. However, a subsequent meta-analysis (18) sug-
gested that acquired late malapposition may be associated
with 6 times higher risk for late stent thrombosis. How-
ever, its relationship with the need for late revascularization
procedure is unknown. Conversely, this delayed rise in
revascularization procedure among diabetic patients treated
with DES was not observed in large registries with follow-up
periods of 2.5 years (12) and 3 years (14).
Nonetheless, most patients requiring repeat procedures
underwent percutaneous coronary intervention. Generally,
individuals tend to have a natural distaste for surgery and
concerns regarding cognitive decline (19). Although the
figures were not available for 5 years for ARTS, the numbers
undergoing cardiac surgery at 3 years were 6 (3.8%) and 2
(2.1%) for SES and CABG patients, respectively (20). In
other words, DES treatment may have avoided CABG in
96.2% of patients with diabetes and multivessel disease.
For 12 years, Hercules used his strength, ingenuity, and,
sometimes, assistance from some helpful individuals to
complete task after task for King Eurystheus. It has been
almost 15 years since the Bypass Angioplasty Revascular-
ization Investigation (21) alert raised concern for treating
diabetic patients with angioplasty. The field of interven-
tional cardiology has progressed substantially since then,
developing ideas from engineering and drug delivery. The
investigators of ARTS and other studies have shown that
coronary stenting in patients with diabetes and multivessel
disease is relatively safe. Because of the superiority over
BMS, DES is probably the preferred device for percutane-
ous coronary intervention. Novel pharmacological agents
may further improve outcomes among patients with diabe-
tes undergoing coronary stenting (22). Although newer
generations of DES (23,24) have not been shown to be fully
comparable to CABG regarding the need for repeat revas-
cularization, continuous innovation will narrow the efficacy
gap further for patients with diabetes.
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